Samuel A. Shelburne, M.D., Ph.D.

Peer-Reviewed Articles

1. Shropshire WC, Strope B, Selvaraj Anand S, Bremer J, McDaneld P, Bhatti MM, Flores AR, Kalia A, Shelburne SA. Temporal dynamics of genetically heterogeneous extended-spectrum cephalosporin-resistant Escherichia coli bloodstream infections. mSphere:e0018323. e-Pub 2023. PMID: 37427953.
2. DebRoy S, Shropshire WC, Vega L, Tran C, Horstmann N, Mukherjee P, Selvaraj-Anand S, Tran TT, Bremer J, Gohel M, Arias CA, Flores AR, Shelburne SA. Identification of distinct impacts of CovS inactivation on the transcriptome of acapsular group A streptococci. mSystems:e0022723. e-Pub 2023. PMID: 37358280.
3. Horstmann N, Tran CN, Flores AR, Shelburne SA. Hyperphosphorylation of the Group A Streptococcal Control of Virulence Regulator Increases Promoter Occupancy Specifically at Virulence Factor-Encoding Genes. J Bacteriol 205(6):e0011823, 2023. e-Pub 2023. PMID: 37289078.
4. McMahon S, Sahasrabhojane P, Kim J, Franklin S, Chang CC, Jenq RR, Hillhouse AE, Shelburne SA, Galloway-Peña J. Contribution of the Oral and Gastrointestinal Microbiomes to Bloodstream Infections in Leukemia Patients. Microbiol Spectr 11(3):e0041523, 2023. e-Pub 2023. PMID: 37022173.
5. Gerges B, Rolston K, Shelburne SA, Rosenblatt J, Prince R, Raad I. The in vitro activity of delafloxacin and comparator agents against bacterial pathogens isolated from patients with cancer. JAC Antimicrob Resist 5(2):dlad034, 2023. e-Pub 2023. PMID: 36994231.
6. Rolston K, Gerges B, Nesher L, Shelburne SA, Prince R, Raad I. In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer. JAC Antimicrob Resist 5(2):dlad020, 2023. e-Pub 2023. PMID: 36875177.
7. Tran TT, Cabrera NL, Gonzales-Luna AJ, Carlson TJ, Alnezary F, Miller WR, Sakurai A, Dinh AQ, Rydell K, Rios R, Diaz L, Hanson BM, Munita JM, Pedroza C, Shelburne SA, Aitken SL, Garey KW, Dillon R, Puzniak L, Arias CA. Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA. JAC Antimicrob Resist 5(1):dlac131, 2023. e-Pub 2023. PMID: 36601551.
8. Simar SR, Tran TT, Rydell KB, Panesso D, Contreras GA, Munita JM, Cifuentes RO, Abbo LM, Sahasrabhojane P, Dinh AQ, Axell-House DB, Savidge T, Shelburne SA, Hanson BM, Arias CA. Multisite Detection of Tn1549-Mediated vanB Vancomycin Resistance in Multidrug-Resistant Enterococcus faecalis ST6 in Texas and Florida. Antimicrob Agents Chemother 67(1):e0128422, 2023. e-Pub 2022. PMID: 36541772.
9. Schwabkey ZI, Wiesnoski DH, Chang CC, Tsai WB, Pham D, Ahmed SS, Hayase T, Ortega Turrubiates MR, El-Himri RK, Sanchez CA, Hayase E, Frenk Oquendo AC, Miyama T, Halsey TM, Heckel BE, Brown AN, Jin Y, Raybaud M, Prasad R, Flores I, McDaniel L, Chapa V, Lorenzi PL, Warmoes MO, Tan L, Swennes AG, Fowler S, Conner M, McHugh K, Graf T, Jensen VB, Peterson CB, Do KA, Zhang L, Shi Y, Wang Y, Galloway-Pena JR, Okhuysen PC, Daniel-MacDougall CR, Shono Y, Burgos da Silva M, Peled JU, van den Brink MRM, Ajami N, Wargo JA, Reddy P, Valdivia RH, Davey L, Rondon G, Srour SA, Mehta RS, Alousi AM, Shpall EJ, Champlin RE, Shelburne SA, Molldrem JJ, Jamal MA, Karmouch JL, Jenq RR. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med 14(671):eabo3445, 2022. e-Pub 2022. PMID: 36383683.
10. Tamma PD, Komarow L, Ge L, Garcia-Diaz J, Herc ES, Doi Y, Arias CA, Albin O, Saade E, Miller LG, Jacob JT, Satlin MJ, Krsak M, Huskins WC, Dhar S, Shelburne SA, Hill C, Baum KR, Bhojani M, Greenwood-Quaintance KE, Schmidt-Malan SM, Patel R, Evans SR, Chambers HF, Fowler VG, van Duin D, Antibacterial Resistance Leadership Group. Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study. Open Forum Infect Dis 9(11):ofac572, 2022. e-Pub 2022. PMID: 36381622.
11. Shropshire WC, Konovalova A, McDaneld P, Gohel M, Strope B, Sahasrabhojane P, Tran CN, Greenberg D, Kim J, Zhan X, Aitken S, Bhatti M, Savidge TC, Treangen TJ, Hanson BM, Arias CA, Shelburne SA. Systematic Analysis of Mobile Genetic Elements Mediating β-Lactamase Gene Amplification in Noncarbapenemase-Producing Carbapenem-Resistant Enterobacterales Bloodstream Infections. mSystems 7(5):e0047622, 2022. e-Pub 2022. PMID: 36036505.
12. Hayase E, Hayase T, Jamal MA, Miyama T, Chang CC, Ortega MR, Ahmed SS, Karmouch JL, Sanchez CA, Brown AN, El-Himri RK, Flores II, McDaniel LK, Pham D, Halsey T, Frenk AC, Chapa VA, Heckel BE, Jin Y, Tsai WB, Prasad R, Tan L, Veillon L, Ajami NJ, Wargo JA, Galloway-Peña J, Shelburne S, Chemaly RF, Davey L, Glowacki RWP, Liu C, Rondon G, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Valdivia RH, Martens EC, Lorenzi PL, Jenq RR. Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell 185(20):3705-3719.e14, 2022. PMID: 36179667.
13. Bhalodi AA, MacVane SH, Ford B, Ince D, Kinn PM, Percival KM, Bremmer DN, Carr DR, Walsh TL, Bhatti MM, Shelburne SA, Humphries RM, Wolfe K, Rosenbaum ER, Dare RK, Kolev J, Madhusudhan M, Ben-Aderet MA, Morgan MA. Real-World Impact of the Accelerate PhenoTest ® BC Kit on patients with bloodstream infections in IOAS (Improving Outcomes and Antimicrobial Stewardship): A Quasi-Experimental Multicenter Study. Clin Infect Dis 75(2):269-277, 2022. e-Pub 2021. PMID: 34718456.
14. Vega LA, Sanson MA, Cubria MB, Regmi S, Shah BJ, Shelburne SA, Flores AR. The Integrative Conjugative Element ICESpyM92 Contributes to Pathogenicity of Emergent Antimicrobial-Resistant emm92 Group A Streptococcus. Infect Immun 90(8):e0008022, 2022. e-Pub 2022. PMID: 35913172.
15. Rolston KVI, Gerges BZ, Reitzel R, Shelburne SA, Aitken SL, Raad II, Prince RA. In vitro activity of imipenem/releactam and comparator agents against clinical bacterial isolates from patients with cancer. J Glob Antimicrob Resist 29:1-6, 2022. e-Pub 2022. PMID: 35121163.
16. Mojica MF, Humphries R, Lipuma JJ, Mathers AJ, Rao GG, Shelburne SA, Fouts DE, Van Duin D, Bonomo RA. Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC Antimicrob Resist 4(3):dlac040, 2022. e-Pub 2022. PMID: 35529051.
17. Shropshire WC, Dinh AQ, Earley M, Komarow L, Panesso D, Rydell K, Gómez-Villegas SI, Miao H, Hill C, Chen L, Patel R, Fries BC, Abbo L, Cober E, Revolinski S, Luterbach CL, Chambers H, Fowler VG, Bonomo RA, Shelburne SA, Kreiswirth BN, van Duin D, Hanson BM, Arias CA. Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX. mBio 13(2):e0049722, 2022. e-Pub 2022. PMID: 35357213.
18. Contreras GA, Munita JM, Simar S, Luterbach C, Dinh AQ, Rydell K, Sahasrabhojane PV, Rios R, Diaz L, Reyes K, Zervos M, Misikir HM, Sanchez-Petitto G, Liu C, Doi Y, Abbo LM, Shimose L, Seifert H, Gudiol C, Barberis F, Pedroza C, Aitken SL, Shelburne SA, van Duin D, Tran TT, Hanson BM, Arias CA. Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I). Open Forum Infect Dis 9(3):ofab616, 2022. e-Pub 2021. PMID: 35155713.
19. Horstmann N, Myers KS, Tran CN, Flores AR, Shelburne Iii SA. CovS inactivation reduces CovR promoter binding at diverse virulence factor encoding genes in group A Streptococcus. PLoS Pathog 18(2):e1010341, 2022. e-Pub 2022. PMID: 35180278.
20. Franklin S, Aitken SL, Shi Y, Sahasrabhojane PV, Robinson S, Peterson CB, Daver N, Ajami NA, Kontoyiannis DP, Shelburne SA, Galloway-Peña J. Oral and Stool Microbiome Coalescence and Its Association With Antibiotic Exposure in Acute Leukemia Patients. Front Cell Infect Microbiol 12:848580, 2022. e-Pub 2022. PMID: 35433514.
21. DebRoy S, Shropshire WC, Tran CN, Hao H, Gohel M, Galloway-Peña J, Hanson B, Flores AR, Shelburne SA. Characterization of the Type I Restriction Modification System Broadly Conserved among Group A Streptococci. mSphere 6(6):e0079921, 2021. e-Pub 2021. PMID: 34787444.
22. Sanson MA, Vega LA, Shah B, Regmi S, Cubria MB, Horstmann N, Shelburne SA, Flores AR. The LiaFSR transcriptome reveals an interconnected regulatory network in group A Streptococcus. Infect Immun 89(11):IAI0021521, 2021. e-Pub 2021. PMID: 34370508.
23. DebRoy S, Sanson M, Shah B, Regmi S, Vega LA, Odo C, Sahasrabhojane P, McGeer A, Tyrrell GJ, Fittipaldi N, Shelburne SA, Flores AR. Population Genomics of emm4 Group A Streptococcus Reveals Progressive Replacement with a Hypervirulent Clone in North America. mSystems 6(4):e0049521, 2021. e-Pub 2021. PMID: 34374563.
24. DebRoy S, Aliaga-Tobar V, Galvez G, Arora S, Liang X, Horstmann N, Maracaja-Coutinho V, Latorre M, Hook M, Flores AR, Shelburne SA. Genome-wide analysis of in vivo CcpA binding with and without its key co-factor HPr in the major human pathogen group A Streptococcus. Mol Microbiol 115(6):1207-1228, 2021. e-Pub 2020. PMID: 33325565.
25. Shah S, Shelburne S. Skin and Soft Tissue Infections in Non-Human Immunodeficiency Virus Immunocompromised Hosts. Infect Dis Clin North Am 35(1):199-217, 2021. e-Pub 2020. PMID: 33303336.
26. Satlin MJ, Weissman SJ, Carpenter PA, Seo SK, Shelburne SA. American Society of Transplantation and Cellular Therapy Series, 1: Enterobacterales Infection Prevention and Management after Hematopoietic Cell Transplantation. Transplant Cell Ther 27(2):108-114, 2021. PMID: 33781545.
27. Shropshire WC, Aitken SL, Pifer R, Kim J, Bhatti MM, Li X, Kalia A, Galloway-Peña J, Sahasrabhojane P, Arias CA, Greenberg DE, Hanson BM, Shelburne SA. IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort. J Antimicrob Chemother 76(2):385-395, 2021. PMID: 33164081.
28. Reyes-Gibby CC, Wang J, Zhang L, Peterson CB, Do KA, Jenq RR, Shelburne S, Shah DP, Chambers MS, Hanna EY, Yeung SJ, Shete S. Oral microbiome and onset of oral mucositis in patients with squamous cell carcinoma of the head and neck. Cancer. e-Pub 2020. PMID: 32888342.
29. Olvera A, Carter H, Rajan A, Carlin LG, Yu X, Zeng XL, Shelburne S, Bhatti M, Blutt SE, Shroyer NF, Jenq R, Estes MK, Maresso A, Okhuysen PC. Enteropathogenic Escherichia coli Infection in Cancer and Immunosuppressed Patients. Clin Infect Dis. e-Pub 2020. PMID: 32930708.
30. Galloway-Peña JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, Daver NG, Alfayez M, Boddu PC, Khan MAW, Wargo JA, Do KA, Jenq RR, Kontoyiannis DP, Shelburne SA. Gut Microbiome Signatures are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clin Infect Dis 71(1):63-71, 2020. e-Pub 2019. PMID: 31436833.
31. Cabrera NL, Malek AE, Shelburne S, Taremi M, Awadh H, Francisco D, Robins A, Jabbour E, Chemaly RF. Disseminated cytomegalovirus infection with bilateral adrenal pseudotumors masquerading as recurrent hematologic malignancy. Infection 48(3):477-481, 2020. e-Pub 2020. PMID: 32144592.
32. Aitken SL, Sahasrabhojane PV, Kontoyiannis DP, Savidge TC, Arias CA, Ajami NJ, Shelburne SA, Galloway-Peña JR. Alterations of the oral microbiome and cumulative carbapenem exposure are associated with Stenotrophomonas maltophilia infection in patients with acute myeloid leukemia receiving chemotherapy. Clin Infect Dis. e-Pub 2020. PMID: 32544947.
33. Shelburne SA, Dib RW, Endres BT, Reitzel R, Li X, Kalia A, Sahasrabhojane P, Chaftari AM, Hachem R, Vargas-Cruz NS, Jiang Y, Garey K, Fowler VG, Holland TL, Gu J, Miller W, Sakurai A, Arias CA, Aitken SL, Greenberg DE, Kim J, Flores AR, Raad I. Whole-genome sequencing of Staphylococcus epidermidis bloodstream isolates from a prospective clinical trial reveals that complicated bacteraemia is caused by a limited number of closely related sequence types. Clin Microbiol Infect 26(5):646.e1-646.e8, 2020. e-Pub 2019. PMID: 31639470.
34. Robinson S, Peterson CB, Sahasrabhojane P, Ajami NJ, Shelburne SA, Kontoyiannis DP, Galloway-Peña JR. Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia. mSphere 5(2), 2020. e-Pub 2020. PMID: 32295867.
35. Rolston KVI, Gerges B, Shelburne S, Aitken SL, Raad I, Prince RA. Activity of Cefiderocol and Comparators against Isolates from Cancer Patients. Antimicrob Agents Chemother 64(5), 2020. e-Pub 2020. PMID: 32071053.
36. Arora S, Li X, Hillhouse A, Konganti K, Little SV, Lawhon SD, Threadgill D, Shelburne S, Hook M. Staphylococcus epidermidis MSCRAMM SesJ Is Encoded in Composite Islands. mBio 11(1), 2020. e-Pub 2020. PMID: 32071265.
37. Kim J, Greenberg DE, Pifer R, Jiang S, Xiao G, Shelburne SA, Koh A, Xie Y, Zhan X. VAMPr: VAriant Mapping and Prediction of antibiotic resistance via explainable features and machine learning. PLoS Comput Biol 16(1):e1007511, 2020. e-Pub 2020. PMID: 31929521.
38. Muñoz NM, Minhaj AA, Dupuis CJ, Ensor JE, Golardi N, Jaso JM, Dixon KA, Figueira TA, Galloway-Peña JR, Hill L, Shelburne SA, Tam AL. What Are the Effects of Irreversible Electroporation on a Staphylococcus aureus Rabbit Model of Osteomyelitis?. Clin Orthop Relat Res. e-Pub 2019. PMID: 31393339.
39. Galloway-Peña JR, Peterson CB, Malik F, Sahasrabhojane PV, Shah DP, Brumlow CE, Carlin LG, Chemaly RF, Im JS, Rondon G, Felix E, Veillon L, Lorenzi PL, Alousi AM, Jenq RR, Kontoyiannis DP, Shpall EJ, Shelburne SA, Okhuysen PC. Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study. Open Forum Infect Dis 6(5):ofz173, 2019. e-Pub 2019. PMID: 31065565.
40. Benanti GE, Brown ART, Shigle TL, Tarrand JJ, Bhatti MM, McDaneld PM, Shelburne SA, Aitken SL. Carbapenem versus Cefepime or Piperacillin-Tazobactam for the Empiric Treatment of Extended Spectrum β-lactamase Producing Escherichia coli Bacteremia in Patients with Hematologic Malignancy. Antimicrob Agents Chemother 63(2), 2019. e-Pub 2019. PMID: 30509935.
41. Tran TT, Mishra NN, Seepersaud R, Diaz L, Rios R, Dinh AQ, Garcia-de-la-Maria C, Rybak MJ, Miro JM, Shelburne SA, Sullam PM, Bayer AS, Arias CA. Mutations in cdsA and pgsA Correlate With Daptomycin Resistance in S. mitis/oralis. Antimicrob Agents Chemother 63(2), 2019. e-Pub 2019. PMID: 30509945.
42. DebRoy S, Li X, Kalia A, Galloway-Pena J, Shah BJ, Fowler VG, Flores AR, Shelburne SA. Identification of a chimeric emm gene and novel emm pattern in currently circulating strains of emm4 Group A Streptococcus. Microb Genom 4(11), 2018. e-Pub 2018. PMID: 30412460.
43. Horstmann N, Tran CN, Brumlow C, DebRoy S, Yao H, Nogueras Gonzalez G, Makthal N, Kumaraswami M, Shelburne SA. Phosphatase activity of the control of virulence sensor kinase CovS is critical for the pathogenesis of group A streptococcus. PLoS Pathog 14(10):e1007354, 2018. e-Pub 2018. PMID: 30379939.
44. Foolad F, Taylor BD, Shelburne SA, Arias CA, Aitken SL. Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review. J Antimicrob Chemother 73(9):2277-2283, 2018. PMID: 29547977.
45. Rolston KVI, Reitzel R, Vargas-Cruz N, Shelburne SA, Raad II, Prince RA. In vitro activity of tedizolid and comparator agents against clinical Gram-positive isolates recovered from patients with cancer. Diagn Microbiol Infect Dis 91(4):351-353, 2018. e-Pub 2018. PMID: 29661529.
46. Flores AR, Chase McNeil J, Shah B, Van Beneden C, Shelburne SA. Capsule-Negative emm Types Are an Increasing Cause of Pediatric Group A Streptococcal Infections at a Large Pediatric Hospital in Texas. J Pediatric Infect Dis Soc. e-Pub 2018. PMID: 30085121.
47. Li X, Arias CA, Aitken SL, Galloway Peña J, Panesso D, Chang M, Diaz L, Rios R, Numan Y, Ghaoui S, DebRoy S, Bhatti MM, Simmons DE, Raad I, Hachem R, Folan SA, Sahasarabhojane P, Kalia A, Shelburne SA. Clonal Emergence of Invasive Multidrug-Resistant Staphylococcus epidermidis Deconvoluted via a Combination of Whole-Genome Sequencing and Microbiome Analyses. Clin Infect Dis 67(3):398-406, 2018. PMID: 29546356.
48. Folan SA, Marx KR, Tverdek FP, Raad I, Mulanovich VE, Tarrand JJ, Shelburne SA, Aitken SL. Clinical Outcomes Associated With Linezolid Resistance in Leukemia Patients With Linezolid-Resistant Staphylococcus epidermidis Bacteremia. Open Forum Infect Dis 5(7):ofy167, 2018. e-Pub 2018. PMID: 30090838.
49. Lacourt TE, Kavelaars A, Ohanian M, Shah ND, Shelburne SA, Futreal A, Kontoyiannis DP, Heijnen CJ. Patient-reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia. Oncotarget 9(58):31244-31252, 2018. e-Pub 2018. PMID: 30131851.
50. Lacourt TE, Kavelaars A, Galloway-Peña JR, Sahasrabhojane PV, Shah ND, Futreal A, Kontoyiannis DP, Shelburne SA, Heijnen CJ. Associations of inflammation with symptom burden in patients with acute myeloid leukemia. Psychoneuroendocrinology 89:203-208, 2018. PMID: 29414033.
51. Galloway-Peña J, DebRoy S, Brumlow C, Li X, Tran TT, Horstmann N, Yao H, Chen K, Wang F, Pan BF, Hawke DH, Thompson EJ, Arias CA, Fowler VG, Bhatti MM, Kalia A, Flores AR, Shelburne SA. Hypervirulent group A Streptococcus emergence in an acaspular background is associated with marked remodeling of the bacterial cell surface. PLoS One 13(12):e0207897, 2018. e-Pub 2018. PMID: 30517150.
52. Galloway-Pena JR, Brumlow C, SHELBURNE SA. Impact of the microbiota on bacterial infections during cancer treatment. Trends in Microbiology, 2017.
53. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Sloane RS, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Sanchez EMR, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 2017. PMID: 29097493.
54. Shelburne SA, Kim J, Munita JM, Sahasrabhojane P, Shields RK, Press EG, Li X, Arias CA, Cantarel B, Jiang Y, Kim MS, Aitken SL, Greenberg DE. Whole Genome Sequencing Accurately Identifies Resistance to Extended Spectrum β-Lactams for Major Gram-Negative Bacterial Pathogens. Clin Infect Dis 65(5):738-745, 2017. PMID: 28472260.
55. Horstmann N, Sahasrabhojane P, Yao H, Su X, Shelburne SA. Use of a phosphorylation site mutant to identify distinct modes of gene repression by the control of virulence regulator(CovR) in Streptococcus pyogenes. J Bacteriol 199(18), 2017. PMID: 28289082.
56. DiPippo AJ, Tverdek FP, Tarrand JJ, Munita JM, Tran TT, Arias CA, SHELBURNE SA, Aitken SL. Daptomycin non-susceptible Enterococcus faecium in leukemia patients: Role of prior daptomycin exposure. Journal of Infection 74(3):243-7, 2017.
57. Reyes-Gibby CC, Melkonian SC, Wang J, Yu RK, SHELBURNE SA, Lu C, Gunn GB, Chambers MS, Hanna EY, Yeung SJ, Shete S. Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis. PLoS One 12(7), 2017.
58. Flores AR, Luna RA, Runge JK, Shelburne SA 3rd, Baker CJ.. Cluster of fatal group A streptococcal emm87 infection within a single family: molecular basis for invasion and transmission. J Infect Dis, 2017. PMID: 28383686.
59. Rolston KV, Jamal MA, Nesher L, SHELBURNE SA , Raad I, Prince RA. In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients. International Journal of Antimicrobial Agents 249(4):416-421, 2017.
60. Munita JM, Aitken SL, Miller WR, Perez F, Rosa R, Shimose LA, Lichtenberger PN, Abbo LM, Jain R, Nigo M, Wanger A, Araos R, Tran TT, Adachi J, Rakita R, Shelburne S, Bonomo RA, Arias CA.. Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa. Clin Infect Dis, 2017. PMID: 28329350.
61. Wadsworth WD, Argiento R, Guindani M, Galloway-Pena J, Shelburne SA. An integrative Bayesian Dirichlet-multinomial regression model for the analysis of taxonomic abundances in microbiome data. BMC Bioinformatics 18(1):185, 2017.
62. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Wadsworth WD, Fellman BM, Ajami NJ, Shpall EJ, Daver N, Guindani M, Petrosino JF, Kontoyiannis DP, SHELBURNE SA. Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. Genome Medicine 9(1):21, 2017.
63. Bhatti MD, Kalia A, Sahasrabhojane P, Kim J, Greenberg DE, SHELBURNE SA. Identification and whole genome sequencing of the first case of Kosakonia radicincitans causing a human bloodstream infection. Frontiers in Microbiology 8(62), 2017.
64. Galloway-Peña JR, Jenq RR, SHELBURNE SA. Can consideration of the microbiome improve antimicrobial utilization and treatment outcomes in the oncology Patient?. Clinical Cancer Research 23(13):3263-8, 2017.
65. Munita JM, SHELBURNE SA, Greenberg DE, Arias CA.. The growing threat of antimicrobial resistance. Texas Medicine 1:113(2):48-52, 2017.
66. DebRoy S, Saldaña M, Travisany D, Montano A, Galloway-Peña J, Horstmann N, Yao H, González M, Maass A, Latorre M, Shelburne SA. A Multi-Serotype Approach Clarifies the Catabolite Control Protein A Regulon in the Major Human Pathogen Group A Streptococcus. Sci Rep 6:32442, 2016. e-Pub 2016. PMID: 27580596.
67. Mojica MF, Ouellette CP, Leber A, Becknell MB, Ardura MI, Perez F, Shimamura M, Bonomo RA, Aitken SL, Shelburne SA. Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient. Antimicrob Agents Chemother 60(9):5130-4, 2016. e-Pub 2016. PMID: 27551008.
68. Zhu L, Olsen RJ, Horstmann N, Shelburne SA, Fan J, Hu Y, Musser JM. Intergenic Variable-Number Tandem-Repeat Polymorphism Upstream of rocA Alters Toxin Production and Enhances Virulence in Streptococcus pyogenes. Infect Immun 84(7):2086-93, 2016. e-Pub 2016. PMID: 27141081.
69. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer 122(14):2186-96, 2016. PMID: 27142181.
70. Aitken SL, Tarrand JJ, Deshpande LM, Tverdek FP, Jones AL, Shelburne SA, Prince RA, Bhatti MM, Rolston KV, Jones RN, Castanheira M, Chemaly R. High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center. Clin Infect Dis, 2016. PMID: 27313265.
71. Shukla BS, Shelburne S, Reyes K, Kamboj M, Lewis JD, Rincon SL, Reyes J, Carvajal LP, Panesso D, Sifri CD, Zervos MJ, Pamer EG, Tran TT, Adachi J, Munita JM, Hasbun R, Arias CA.. Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?. Clin Infect Dis 15;62(12):1514-20, 2016.
72. Petrosyan V, Holder M, Ajami NJ, Petrosino JF, Sahasrabhojane P, Thompson EJ, Kalia A, Shelburne SA. Complete Genome Sequence of Streptococcus mitis Strain SVGS_061 Isolated from a Neutropenic Patient with Viridans Group Streptococcal Shock Syndrome. Genome Announc 4(2), 2016. PMID: 27056234.
73. Galloway-Peña J, Clement ME, Sharma Kuinkel BK, Ruffin F, Flores AR, Levinson H, Shelburne SA, Moore Z, Fowler VG. Application of Whole-Genome Sequencing to an Unusual Outbreak of Invasive Group A Streptococcal Disease. Open Forum Infect Dis 3(1):ofw042, 2016. PMID: 27006966.
74. Rolston KV, Wang W, Nesher L, Shelburne SA, Prince RA. In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients. J Antibiot, 2015. PMID: 26626876.
75. Shelburne SA, Ajami NJ, Chibucos MC, Beird HC, Tarrand J, Galloway-Peña J, Albert N, Chemaly RF, Ghantoji SS, Marsh L, Pemmaraju N, Andreeff M, Shpall EJ, Wargo JA, Rezvani K, Alousi A, Bruno VM, Futreal PA, Petrosino JF, Kontoyiannis DP.. Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis 10(10):11, 2015. PMID: 26556047.
76. Miller EW, Danger JL, Ramalinga AB, Horstmann N, Shelburne SA, Sumby P.. Regulatory rewiring confers serotype-specific hyper-virulence in the human pathogen group A Streptococcus. Mol Microbiol. e-Pub 2015. PMID: 26192205.
77. Flores AR, Galloway-Peña J, Sahasrabhojane P, Saldaña M, Yao H, Su X, Ajami NJ, Holder ME, Petrosino JF, Thompson E, Margarit Y Ros I, Rosini R, Grandi G, Horstmann N, Teatero S, McGeer A, Fittipaldi N, Rappuoli R, Baker C, Shelburne SA. Sequence type 1 group B Streptococcus, an emerging cause of invasive disease in adults, evolves by small genetic changes. PNAS 19;112(20):6431-6, 2015. PMID: 25941374.
78. Horstmann N, Sahasrabhojane P, Saldaña M1, Ajami NJ, Flores AR, Sumby P, Liu CG, Yao H, Su X, Thompson E, Shelburne SA. Characterization of the Effect of the Histidine Kinase CovS on Response Regulator Phosphorylation in Group A Streptococcus. Infect Immun 83(3):1068-77, 2015. PMID: 25561708.
79. Galloway-Peña JR, Liang X, Singh KV, Yadav P, Chang C, La Rosa SL, Shelburne S, Ton-That H, Höök M, Murray BE.. The identification and functional characterization of WxL proteins from Enterococcus faecium reveal surface proteins involved in extracellular matrix interactions. J Bacteriol 197(5):882-92, 2015. PMID: 25512313.
80. Teatero S, Athey TB, Van Caeseele P, Horsman G, Alexander DC, Melano RG, Li A, Flores AR, Shelburne SA 3rd, McGeer A, Demczuk W, Martin I, Fittipaldi N.. Emergence of Serotype IV Group B Streptococcus Adult Invasive Disease in Manitoba and Saskatchewan, Canada, Is Driven by Clonal Sequence Type 459 Strains. J Clin Microbiol 53(9):2919-26, 2015. PMID: 26135871.
81. Holland T, Fowler VG Jr, Shelburne SA 3rd. Invasive gram-positive bacterial infection in cancer patients. Clin Infect Dis(5):S331-4, 2014. PMID: 25352626.
82. Shelburne SA 3rd, Chaftari AM, Jamal M, Al Wohoush I, Jiang Y, Abughazaleh S, Cairo J, Raad S, Debiane L, Raad I. Identification and characterization of catheter-related bloodstream infections due to viridans group streptococci in patients with cancer. Am J Infect Control 42(10):1127-9, 2014. PMID: 25278410.
83. Flores AR, Jewell BE, Olsen RJ, Shelburne SA 3rd, Fittipaldi N, Beres SB, Musser JM.. Asymptomatic carriage of group a streptococcus is associated with elimination of capsule production. Infect Immun 82(9):3958-67. doi: 10.1128/IAI.01788-14, 2014. PMID: 25024363.
84. Jessica Galloway-Peña, Pranoti Sahasrabhojane, Jeffrey Tarrand , Xiang Y. Han, and Samuel A. Shelburne. GyrB Polymorphisms Accurately Assign Invasive Viridans Group Streptococcal Species. J Clin Micro 52(8):2905-12, 2014. PMID: 24899021.
85. Aline El Zakhem, Anne-Marie Chaftari, Ramez Bahu, Gilbert El Helou, Samuel Shelburne, Ying Jiang, Ray Hachem, and Issam Raad. Central Line-Associated Bloodstream Infections Caused by Staphylococcus aureus in Cancer Patients: Clinical Outcome and Management. Annals of Medicine 46(3):163-8, 2014. PMID: 24491173.
86. N Horstmann, M Saldaña, P Sahasrabhojane, H Yao, X Su, E Thompson, A Koller, and SA Shelburne. Dual-Site Phosphorylation of the Control of Virulence Regulator Impacts Group A Streptococcal Global Gene Expression and Pathogenesis. PLoS Pathogens 1;10(5):e1004088, 2014. PMID: 24788524.
87. Shelburne SA, Sahasrabhojane P, Saldana M, Yao H, Su X, Horstmann N, Thompson E, Flores AR.. Streptococcus mitis strains causing severe clinical disease in cancer patients. Emerg Infect Dis 20(5):762-71, 2014. PMID: 24750901.
88. Shelburne SA, Lasky R, Sahasrabhojane P, Tarrand JR; Rolston KV.. Development and Validation of a Clinical Model to Predict the Presence of β-lactam Resistance in Viridans Group Streptococci Causing Bacteremia in Neutropenic Cancer Patients. Clin Infect Dis 15;59(2):223-30, 2014. PMID: 24755857.
89. Sahasrabhojane P, Galloway-Peña J, Velazquez L, Saldaña M, Horstmann N, Tarrand J, Shelburne SA.. Species Level Assessment of the Molecular Basis of Fluoroquinolone Resistance Among Viridans Group Streptococci Causing Bacteremia in Cancer Patients. Int J Antimicrob Agents 43(8):558-62, 2014. PMID: 24721231.
90. Anthony R. Flores, Pranoti Sahasrabhojane, Miguel Saldaña, Jessica Galloway-Peña, Randall J. Olsen, James M. Musser, and Samuel A. Shelburne. Molecular Characterization of an Invasive Phenotype of Group A Streptococcus Arising During Human Infection Using Whole Genome Sequencing of Multiple Isolates From the Same Patient. J Infect Dis 15;209(10):1520-3, 2013. PMID: 24307742.
91. Flores AR, Olsen RJ, Wunsche A, Kumaraswami M, Shelburne SA 3rd, Carroll RK, Musser JM.. Natural variation in the promoter of the gene encoding the Mga regulator alters host-pathogen interaction in group A Streptococcus carrier strains. Infect Immun 81(11):4128-38, 2013. PMID: 23980109.
92. Shelburne SA, Tarrand J, Rolston KV. Review of streptococcal bloodstream infections at a comprehensive cancer care center, 2000-2011. J Infect 66(2):136-46, 2013. PMID: 23182968.
93. White CN, Shelburne S. Streptococcal infections: understanding the various species and strains. JAAPA 25(11):23-4, 2012. PMID: 23620919.
94. Olsen RJ, Laucirica DR, Watkins ME, Feske ML, Garcia-Bustillos JR, Vu C, Cantu C, Shelburne SA, Fittipaldi N, Kumaraswami M, Shea PR, Flores AR, Beres SB, Lovgren M, Tyrrell GJ, Efstratiou A, Low DE, Van Beneden CA, Musser JM. Polymorphisms in Regulator of Protease B (RopB) Alter Disease Phenotype and Strain Virulence of Serotype M3 Group A Streptococcus. J Infect Dis 205(11):1719-29, 2012. PMID: 22262791.
95. Lin E, Bhusal Y, Horwitz D, Shelburne SA, Trautner BW. Overtreatment of enterococcal bacteriuria. Arch Intern Med 9;72(1):33-8, 2012. PMID: 22232145.
96. Horstmann N, Orans J, Valentin-Hansen P, Shelburne SA, Brennan RG. Structural mechanism of Staphylococcus aureus Hfq binding to an RNA A-tract. Nucleic Acids Res 40(21):11023-35, 2012. PMID: 22965117.
97. Shelburne SA, Olsen RJ, Makthal N, Brown NG, Sahasrabhojane P, Watkins EM, Palzkill T, Musser JM, Kumaraswami M. An N-Terminal Signal Peptide Of Vfr Protein Negatively Influences RopB-Dependent SpeB Expression and Attenuates Virulence in Streptococcus pyogenes. Mol Microbiol 82(6):1481-95, 2011. PMID: 22040048.
98. Horstmann N, Sahasrabhojane P, Suber B, Kumaraswami M, Olsen RJ, Flores A, Musser JM, Brennan RG, Shelburne SA. Distinct single amino acid replacements in the control of virulence regulator protein differentially impact streptococcal pathogenesis. PLoS Pathog 7(10):e1002311, 2011. PMID: 22028655.
99. Shelburne SA, Sahasrobhajane P, Suber B, Keith DB, Davenport MT, Horstmann N, Kumaraswami M, Olsen RJ, Brennan RG, Musser JM. Niche-specific contribution to streptococcal virulence of a MalR-regulated carbohydrate binding protein. Mol Microbiol 81(2):500-14, 2011. PMID: 21645132.
100. Carroll RK, Shelburne SA, Olsen RJ, Suber B, Sahasrabhojane P, Kumaraswami M, Beres SB, Shea PR, Flores AR, Musser JM. Naturally occurring single amino acid replacements in a regulatory protein alter streptococcal gene expression and virulence in mice. J Clin Invest 121(5):1956-68, 2011. PMID: 21490401.
101. Kung DH, Hubenthal EA, Kwan JY, Shelburne SA, Goodman JC, Kass JS. Toxoplasmosis myelopathy and myopathy in an AIDS patient: a case of immune reconstitution inflammatory syndrome?. Neurologist 17(1):49-51, 2011. PMID: 21192196.
102. Shelburne SA, Olsen RJ, Suber B, Sahasrabhojane P, Sumby P, Brennan RG, Musser JM. A combination of independent transcriptional regulators shapes bacterial virulence gene expression during infection. PLoS Pathog 19;6(3):e1000817, 2010. PMID: 20333240.
103. Shelburne SA, Keith DB, Davenport MT, Beres SB, Carroll RK, Musser JM. Contribution of AmyA, an extracellular alpha-glucan degrading enzyme, to group A streptococcal host-pathogen interaction. Mol Microbiol 74(1):159-74, 2009. PMID: 19735442.
104. Musser JM, Shelburne SA. A decade of molecular pathogenomic analysis of group A Streptococcus. J Clin Invest 119(9):2455-63, 2009. PMID: 19729843.
105. Treviño J, Perez N, Ramirez-Peña E, Liu Z, Shelburne SA, Musser JM, Sumby P. CovS simultaneously activates and inhibits the CovR-mediated repression of distinct subsets of group A Streptococcus virulence factor-encoding genes. Infect Immun 77(8):3141-9, 2009. PMID: 19451242.
106. Safdar A, Shelburne SA, Evans SE, Dickey BF. Inhaled therapeutics for prevention and treatment of pneumonia. Expert Opin Drug Saf 8(4):435-49, 2009. PMID: 19538104.
107. Olsen RJ, Shelburne SA, Musser JM. Molecular mechanisms underlying group A streptococcal pathogenesis. Cell Microbiol 11(1):1-12, 2009. PMID: 18710460.
108. Livorsi DJ, Daver NG, Atmar RL, Shelburne SA, White AC, Musher DM. Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect 57(2):128-31, 2008. PMID: 18562009.
109. Shelburne SA, Keith DB, Davenport MT, Horstmann N, Brennan RG, Musser JM. Molecular characterization of group A Streptococcus maltodextrin catabolism and its role in pharyngitis. Mol Microbiol 69(2):436-52, 2008. PMID: 18485073.
110. Shelburne SA 3rd, Davenport M, Keith D, Musser JM. The role of complex carbohydrate metabolism in the pathogenesis of invasive streptococci. Trends Microbiol 16(7):318-25, 2008.
111. Shelburne SA, Keith D, Horstmann N, Sumby P, Davenport MT, Graviss EA, Brennan RG, Musser JM. A direct link between carbohydrate utilization and virulence in the major human pathogen group A Streptococcus. Proc Natl Acad Sci U S A 105(5):1698-1703, 2008. PMID: 18230719.
112. Shelburne SA, Singh KV, White AC, Byrne L, Carmer A, Austin C, Graviss E, Stager C, Murray BE, Atmar RL. Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J Clin Microbiol 46(1):198-205, 2008. PMID: 18003801.
113. Daver NG, Shelburne SA, Atmar RL, Giordano TP, Stager CE, Reitman CA, White AC. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect 54(6):539-44, 2007. PMID: 17198732.
114. Shelburne SA, Okorafor N, Sitkiewicz I, Sumby P, Keith D, Patel P, Austin C, Graviss EA, Musser JM. Regulation of polysaccharide utilization contributes to the persistence of group a streptococcus in the oropharynx. Infect Immun 75(6):2981-90, 2007. PMID: 17403878.
115. Shelburne SA, Fang H, Okorafor N, Sumby P, Sitkiewicz I, Keith D, Patel P, Austin C, Graviss EA, Musser JM, Chow DC. MalE of group A Streptococcus participates in the rapid transport of maltotriose and longer maltodextrins. J Bacteriol 189(7):2610-7, 2007. PMID: 17259319.
116. Shelburne SA, Greenberg SB, Aslam S, Tweardy DJ. Successful ceftriaxone therapy of endocarditis due to penicillin non-susceptible viridans streptococci. J Infect 54(2):e99-101, 2007. PMID: 16824611.
117. Gonzalez BE, Rueda AM, Shelburne SA, Musher DM, Hamill RJ, Hulten KG. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol 27(10):1051-6, 2006. PMID: 17006811.
118. Kaka AS, Rueda AM, Shelburne SA, Hulten K, Hamill RJ, Musher DM. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58(3):680-3, 2006. PMID: 16840428.
119. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 57(2):167-70, 2006. PMID: 16354748.
120. Shelburne SA, Sumby P, Sitkiewicz I, Okorafor N, Granville C, Patel P, Voyich J, Hull R, DeLeo FR, Musser JM. Maltodextrin utilization plays a key role in the ability of group A Streptococcus to colonize the oropharynx. Infect Immun 74(8):4605-14, 2006. PMID: 16861648.
121. Shelburne SA, Sumby P, Sitkiewicz I, Granville C, DeLeo FR, Musser JM. Central role of a bacterial two-component gene regulatory system of previously unknown function in pathogen persistence in human saliva. Proc Natl Acad Sci U S A 102(44):16037-42, 2005. e-Pub 2005. PMID: 16249338.
122. Shelburne SA, Visnegarwala F, Adams C, Krause KL, Hamill RJ, White AC. Unusual manifestations of disseminated Histoplasmosis in patients responding to antiretroviral therapy. Am J Med 118(9):1038-41, 2005. PMID: 16164892.
123. Shelburne SA, Granville C, Tokuyama M, Sitkiewicz I, Patel P, Musser JM. Growth characteristics of and virulence factor production by group A Streptococcus during cultivation in human saliva. Infect Immun 73(8):4723-31, 2005. PMID: 16040985.
124. Shelburne SA, Darcourt J, White AC, Greenberg SB, Hamill RJ, Atmar RL, Visnegarwala F. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 40(7):1049-52, 2005. PMID: 15825000.
125. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, Hamill RJ. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19(4):399-406, 2005. PMID: 15750393.
126. Shelburne SA, Musher DM, Hulten K, Ceasar H, Lu MY, Bhaila I, Hamill RJ. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother 48(10):4016-9, 2004. PMID: 15388469.
127. Shelburne SA, Musser JM. Virulence gene expression in vivo. Curr Opin Microbiol 7(3):283-9, 2004. PMID: 15196497.
128. Shelburne SA, Kielhofner MA, Tiwari PS. Cerebellar involvement in legionellosis. South Med J 97(1):61-4, 2004. PMID: 14746424.
129. Shelburne SA, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 5(2):67-79, 2003. PMID: 12876896.
130. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, Gathe JC, Visnegarwala F, Trautner BW. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81(3):213-27, 2002. PMID: 11997718.

Invited Articles

1. Hanage WP, Shelburne SA. Streptococcus pyogenes with reduced susceptibility to β-lactams: how big an alarm bell?. Clin Infect Dis 71(1):205-206, 2020. e-Pub 2019. PMID: 31630163.
2. Flores AR, Shelburne SA. Toward an understanding of group A streptococcal transmission dynamics using national-level surveillance. Clin Infect Dis 70(7):1482-1483, 2020. PMID: 31408107.

Abstracts

1. Annoe N. Koenig, Chang-Gong Lui, Jianhua Zhang, Peter C. Hu, Erika J. Thompson, Samuel A. Shelburne, Awdhesh Kalia. Population Genomics of the Streptococcus dysgalactiae subspecies equisimilis FCT-locus Reveals a Diverse Array of FCT Architectures & Shared Gene Contact with Group A Streptoccus. ASM Microbe 2019, 2019.
2. S. L. Aitken SL, Bhatti M, Sahasrabhojane P, Galloway-Pena J, Li X, Tverdek FP, Reeves C, McDaneld P, Greenberg D, Shelburne S. Epidemiology and Mechanisms of Carbapenem Resistance in Recurrent Extended-Spectrum β-lactamase- Producing Enterobacteriaceae Bacteremia. Infectious Diseases of America Annual Meeting, 2018.
3. Wilson Dib R, Li X, Shelburne SA, Chaftari AM, Hachem RY, Reitzel R, Vargas-Cruz N, Holland TL, Fowler Jr VG, Raad I. Whole Genome Sequencing Analysis of a Large Cohort of Staphylococcus epidermidis Blood Culture Positive Isolates from a Multicenter Clinical Trial. Infectious Diseases of America Annual Meeting, 2018.
4. Contreras G, Munita JM, Reyes KC, Sahasrabhojane P, Misikir H, Garza H, Zervos MJ, Aitken SL, Shelburne SA, Arias C. VENOUS 1: A Prospective Multicenter Cohort Study of Enterococcal Bacteremia. Infectious Diseases of America Annual Meeting, 2018.
5. Flores AR, Galloway-Pena J, Shelburne III SA. High prevalence of antimicrobial resistance genes uncovered through whole genome sequencing of sequence Type 1 Group B Streptococcus. ASM Microbe 2018, 2018.
6. Galloway-Peña J, DebRoy S, Brumlow C, Li X, Horstmann N, Yao H, Chen K, Bhatti M, Kalia A, Shelburne S. Hypervirulent Group A Streptococcus Emergence in an Acaspular Background is Associated with Marked Remodeling of the Bacterial Cell Surface. Research Retreat, Division of Internal Medicine, MD Anderson Cancer Center, 2018. e-Pub 2018.
7. Horstmann N, Tran C, DebRoy S, Brumlow C; Yao H, Makthal N, Kumaraswami M, Shelburne S. CovS phosphatase activity is pivotal for Streptococcus pyogenes virulence. Research Retreat, Division of Internal Medicine, MD Anderson Cancer Center, 2018.
8. Contreras G, Diaz L, Rios R, Reyes KC, Kamboj M, Lewis J, Rincon S, Reyes J, Carvajal LP, Panesso D, Sifri CD, Zervos M, Pamer E, Tran TT, Shelburne S, Munita J, Arias C. A Whole Genome Sequencing (WGS) Approach to Predict Daptomycin (DAP) Susceptibility of Enterococcus faecium. Infectious Diseases of America Annual Meeting, 2017.
9. Wilson Dib R, Numan Y, Li X, Kalia A, Raad I, SHELBURNE SA. Invasive Staphylococcus epidermidis isolates are highly clonal and distinct from commensal strains: time for a new paradigm in infection control?. Infectious Diseases Society of America Annual Meeting, 2017.
10. Jandhyala D, Mulanovich VE, Aitken S, Tverdek F, Marx K ,Chemaly R, , Rolston KV, SHELBURNE SA. Prophylactic antibiotic therapy and bloodstream infections in leukemia patients presenting to the emergency center. Infectious Diseases Society of America Annual Meeting, 2017.
11. Aitken S, Jandhyala D, Mulanovich VE Marx K, Tverdek F, Chemaly R, Rolston KV, SHELBURNE SA. Patterns of linezolid and daptomycin use in leukemia patients with neutropenic fever presenting to the emergency center. Infectious Diseases Society of America Annual Meeting, 2017.
12. Jandhyala D, Mulanovich VE, Aitken S, Tverdek F, Chemaly R, Marx K, Rolston KV, SHELBURNE SA. A contemporary analysis of neutropenic fever in leukemia patients presenting to the emergency center – importance of pneumonia. Infectious Diseases Society of America Annual Meeting, 2017.
13. Munita J, Sahasrabhojane P, Petitto G,Araos R,Wanger A, Aitken S, SHELBURNE SA Arias CA. Prospective study of enterococcal bacteremia in cancer vs. non-cancer populations: one disease, two tales. Infectious Diseases Society of America Annual Meeting, 2017.
14. Galloway-Peña J, Smith D, Wadsworth WD, Ajami N, Guindani M, Petrosino J, SHELBURNE SA. The effects of antibiotic exposure on microbiome diversity, microbiome stability, and clinical outcomes during induction remission chemotherapy in acute myeloid leukemia patients. 26th Annual Keck Research Conference Progress and Challenges in Combating Antimicrobial Resistance, 2017.
15. Galloway-Pena JR, Shah DP, Sahasrabhojane P, Brunlow CE, Carlin LG, Peterson BC, Alousi AM, Shpall EJ, Chemaly RF, Kontoyiannis DP, SHELBURNE SA, Okhuysen PC. Longitudinal fecal microbiome and metabolite analyses identifies potential biomarkers for prediction of graft vs. host disease in hematopoietic stem cell transplant recipients. American Society for Microbiology Microbe, 2017.
16. Rolston KV, Reitzel R, Vargas-Cruz S, SHELBURNE SA, Raad II, Prince RA. In vitro activity of tedizolid and comparator agents against clinical isolates from cancer patients. American Society for Microbiology Microbe, 2017.
17. Li X, Numan Y, Kalia A, SHELBURNE SA. Whole genome sequence based identification of a ST-5 sub-cluster of linezolid resistant Staphylococcus epidermidis causing invasive disease in cancer patients. American Society for Microbiology Microbe, 2017.
18. Mishra NN, Seepersaud R, Tran TT, SHELBURNE SA, Miro JM, Rybak MJ, Arias CA, Sullamm PM, Bayer AS. Phenotypic and genotypic characteristics of in vitro selected high level daptomycin resistant (DAP-R) strains of clinically derived Streptococcus mitis. American Society for Microbiology Microbe, 2017.
19. Muñoz N, Minhaj A, Golardi A, Jasso JA, Ensor J, Dixon K, Feldman A, Tomas Appleton-Figueira, Galloway-Peña J, Hill L, SHELBURNE SA,Tam AL. Oral and gut microbiome temporal variability in hospitalized cancer patients. Keystone Symposium on Microbiome Health and Disease, 2017.
20. Galloway-Peña J,Shah D, Sahasrabohjane P, Brumlow C, Carlin L, Peterson L, Alousi A, Shpall E, Chemaly R, Kontoyiannis D, SHELBURNE SA, Okhuysen P. Irreversible electroporation combined with parenteral antibiotics enhances treatment of osteomyelitis caused by Staphylococcus aureus in a rabbit model. Radiological Society of North America (RSNA) Conference, 2017.
21. Argiento R, Guindani M, Vannucci M, Wadsworth D, Galloway-Pena J, Shelburne S. A Bayesian Dirichlet-Multinomial Regression Model for the Analysis of Taxonomic Abundances in Microbiome data. CMStatistics 2016, 2016.
22. Nina M. Muñoz, Adeeb A. Minhaj, Jessica R. Galloway-Peña, Marites P. Melancon, Samuel A. Shelburne, Alda L. Tam.. Irreversible electroporation for control of osteomyelitis caused by Staphylococcus aureus. SIR 2016, 2016.
23. DiPippo AJ, Tverdek FP, Tarrand JJ, Munita JM, Tran TT, Arias CA, SHELBURNE SA, Aitken SL. Daptomycin non-susceptible Enterococcus faecium in leukemia patients: Role of prior daptomycin exposure. Infectious Diseases Society of America Annual Meeting, 2016.
24. Folan SA, Tverdek F, Tarrand JF, SHELBURNE SA, Raad I, Mulanovich VE, Marx KR, Aitken SL. Empiric linezolid use is associated with adverse short term outcomes in patients with linezolid-resistant Staphylococcus epidermidis bloodstream infections. Infectious Diseases Society of America Annual Meeting, 2016.
25. Galloway-Pena, J; Shelburne, SA. Tri-genomic Approach to Investigate Host-Pathogen-Commensal Interaction in a Leukemic Patient with Mucormycosis. ICAAC/ICC 2015-San Diego, CA, 2015.
26. Galloway-Pena, J; Shelburne, SA. Prospective Cohort Study of the Oral and Fecal Microbiome During Induction Remission Chemotherapy in Acute Myelogenous Leukemia. ICAAC/ICC, San Diego, CA, 2015.
27. Jessica Galloway-Peña PhD, Daniel Smith PhD, Pranoti Sahasrabhojane , Nadim Ajami PhD, Andy Futreal PhD, Joseph Petrosino PhD , Dimitrios Kontoyiannis MD ScD, Samuel Shelburne III MD, PhD. Temporal Instability of the Oral and Stool Microbiomes During Induction Chemotherapy for Acute Myeloid Leukemia. Cell-CHIN-Symposium: Human Immunity and the Microbiome in health and Disease 2015, 2015.
28. Galloway-Pena, J; Shelburne,SA. First Steps in Analyzing Vaginal Microbiome Data: A Clinically Applied Analysis Discussion. Joint Statistical Meeting 2016, 2015.
29. Galloway-Pena, J; Shelburne, SA. Application of a Tri- Genomic Approach to Study Host-Pathogen-Commensal Interaction and Infectious Disease Susceptibility. 1st Place in Clinical Research at the Division of Internal Medicine Research Retreat, 2015.
30. Galloway-Pena, J; Shelburne, SA. Monitoring The Microbiome in Leukemia Patients Could Reduce Infections During Chemotherapy. Podcast and live stream internet interview, ASM Live at ICAAC/ICC, 2015.
31. Horstmann N,Saldana M,Sahasrabhojane P, Yao H, Su X,Thompson E, Koller A, Shelburne SA. Regulation of dual-site phosphorylation of response regulator CovR and its impact on group A streptococcus global gene expression and virulence. 8th International Conference on Gram-Positive Microorganisms, Montecatini Terme, 2015.
32. Malik F, Okhuysen P, Alousi A, Shpall E, SHELBURNE SA, Petrosino J, Rezvani K, Ajami NJ, Ghosh N, Carlin L, Chemaly R. Fecal indole correlates with loss of microbiome diversity in hematopoietic stem cell transplant (HSCT) recipients with and without intestinal graft versus host disease (iGVHD). Infectious Diseases Society of America Annual Meeting, 2015.
33. Shukla B, SHELBURNE SA, Reyes K, Lewis J, Rincon S, Panesso D, Adachi J, Costi D. Sifri, MD, Zervos M,Munita J, Hasbun R, Arias C. Influence of MIC in clinical outcomes of Enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint?. Infectious Diseases Society of America Annual Meeting, 2015.
34. Teatero S, Athey TB, Van Caeseele P, Horsman G, Alexander DC, Melano RG, Li A, Flores AR, SHELBURNE SA, McGeer A, Demczuk W, Martin I, Fittipaldi N. Emergence of serotype IV group B Streptococcus adult invasive disease in Manitoba and Saskatchewan, Canada, is driven by clonal sequence type 459 strains. American Society for Microbiology Annual Meeting, 2015.
35. Aitken SL, Tarrand JJ, Deshpande LM, Tverdek FP, SHELBURNE SA, Chemaly RF, Prince RA, Rolston KV, Jones RN, Castanheira M. Dissemination of NDM-1 among diverse Enterobacteriaceae in Houston is not related to plasmid-mediated spread. International Congress of Antimicrobial Agents and Chemotherapy, 2015.
36. Jessica Galloway-Peña, Pranoti Sahasrabhojane, Immaculada Margarit , Roberto Rosini, Guido Grandi, Allison McGeer, Sarah Teatero, Nahuel Fittipaldi, Carol Baker, Samuel A. Shelburne, and Anthony R. Flores. Small Genetic Changes Drive Phenotypic Diversity Among Sequence Type 1 Group B Streptococcus, An Emerging Cause of Invasive Disease in Adult Humans. IDWeek (IDSA) 2014 in the Immune Response to Microbial Infection Session, 2014.
37. Galloway-Pena, J; Shelburne, SA. Single Nucleotide Polymorphisms Drive Phenotypic Diversity among Sequence Type 1 Group B Streptococcus, An Emerging Cause Of Invasive Disease In Adult Humans. 2nd Place in Basic Research at the Division of Internal Medicine Research Retreat, 2014.
38. Galloway-Pena, J; Shelburne, SA. Elucidation of the Microbiome Landscape of Acute Myelogenous Leukemia Patients Undergoing Induction Remission Chemotherapy. 1st Place in Clinical Research at the Division of Internal Medicine Research Retreat, 2014.
39. Galloway-Pena, J; Shelburne, SA. Analysis of Fluoroquinolone Resistance In Viridans Group Streptococci Causing Invasive Disease in Cancer Patients. Spring 2014 American Society of Microbiology (ASM) Texas Branch Meeting, 2014.
40. Galloway-Pena, J; Shelburne, SA. Elucidation of the Changes in the Microbiome and its Role in Septicemia and Neutropenic Fever in Acute Myelogenous Leukemia Patients Undergoing Induction Remission Chemotherapy. Invited oral presentation at the Molecular Basis of Infectious Diseases Conference, 2014.
41. Pranoti Sahasrabhojane, MS, Miguel Saldaña, Jessica Galloway-Peña, PhD, Samuel Shelburne, MD, PhD.. Novel insights into the emergence of a hypervirulent group A Streptococcus strain revealed by whole genome sequencing of multiple clinical isolates from the same patient. Symposia on Cancer Research 2013, “Genomic Medicine”,, 2013.
42. Anthony R. Flores, Pranoti Sahasrabhojane, Miguel Saldaña, Jessica Galloway-Peña, Randall J. Olsen, James M. Musser, and Samuel A. Shelburne. Documentation of an Invasive Phenotype of Group A Streptococcus Arising During Human Infection Using Whole Genome Sequencing of Multiple Clinical Isolates From the Same Patient. Symposia on Cancer Research 2013: “Genomic Medicine”, 2013.
43. Shelburne SA, White Candice, Mueller Catherine. Improving the Treatment of Staphylococcus aureus bacteremia. University of Texas Clinical Safety and Effectiveness conference in San Antonio, 2013.
44. Samuel Shelburne, Pranoti Sahasrabhojane, Jeffrey Tarrand, Kenneth Rolston. Development and Validation of a Clinical Model to Predict the Presence of β-lactam Resistance in Viridans Group Streptococci Causing Bacteremia in Neutropenic Cancer Patients. MD Anderson Internal Medicine Research Retreat, 2013.
45. Samuel Shelburne, Pranoti Sahasrobhojane, Jeffrey Tarrand, Hui Yao. Identification and Characterization of Streptococcus mitis Strains Causing Severe Clinical Disease in Cancer Patients. MD Anderson Internal Medicine Research Retreat, 2013.
46. 21. Torres HA, Rallapalli V, Saxena A, Granwehr B, Viola G, Ariza E, Marfatia R, Jiang Y, Adachi J, Chemaly R, SHELBURNE SA, Mulanovich V. Efficacy and safety of antiretovirals in HIV-infected patients with cancer. International Congress of Antimicrobial Agents and Chemotherapy, 2013.
47. SHELBURNE SA, Sahasrabhojane P, Tarrand JJ, Rolston KV. Development and validation of a clinical model to predict the presence of β-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer Patients. MD Anderson Internal Medicine Research Retreat, 2013.
48. Shelburne SA, Tarrand J, Rolston K.. Epidemiology, Treatment, and Outcomes of Viridans Group Streptococcal Bloodstream Infections in the Era of High Rates of Antimicrobial Prophylaxis and Empiric Vancomycin Use. Infectious Diseases Society of America 2012, San Diego CA, 2012.
49. Shelburne SA, Sahasrobhojane P, Saldana M.. Identification and Genome-Level Characterization of Highly Virulent Viridians Group Streptococci Causing Invasive Disease in Patients with Malignancy. Infectious Diseases Society of America 2012. San Diego CA, 2012.
50. Shelburne SA, Tarrand J, Rolston K.. Invasive Streptococcal Infections at a United States Cancer Center 2000-2011. Infectious Diseases Society of America 2012. San Diego CA, 2012.
51. Shelburne SA, Tarrand J. Viridans Group Streptococcal Bloodstream and Alpha Streptococcal Shock Syndrome Rates are Increasing in the Era of Antimicrobial Prophylaxis. MD Anderson Internal Medicine Research Retreat, 2012.
52. Shelburne SA, Carroll RK, Olsen RJ, Suber B, Sahasrabhojane P, Kumaraswami M, Beres SB, Shea PR, Flores AR, Musser JM. Naturally occurring single amino acid replacements in a regulatory protein alter streptococcal gene expression and virulence in mice. Program and abstracts of the American Society for Clinical Investigation/Association of American Physicians Joint Meeting, Chicago, IL and The MDACC Department of Internal Medicine Research Retreat, 2011.
53. Horstmann N, Sahasrabhojane P, Suber B, Kumaraswami M, Olsen RJ, Flores A, Musser JM, Brennan RG, Shelburne SA. Distinct single amino Acid replacements in the control of virulence regulator protein differentially impact streptococcal pathogenesis. International Congress of Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011.
54. Lin E, Bhusal Y, Horwitz D, SHELBURNE SA, Trautner B. Enterococcal bacteriuria is often overtreated and rarely leads to infectious complications. Infectious Diseases Society of America Annual Meeting, 2011.
55. Shelburne SA, Suber B, Sahasrobhojane P. A MalR-regulated protein that binds linear glucose polymers is critical to streptococcal oropharyngeal adherence. MDACC Department of Internal Medicine Research Retreat, 2010.
56. Lin E, Horowitz D, Bhusal Y, Roig I, Shelburne SA, Trautner B. Asymptomatic enterococcal bacteruria has a low rate of infectious complications. Program and abstracts of the 48th Annual IDSA Meeting, Vancouver, BC, 2010.
57. Lin E, Horwitz D, Bhusal Y, Roig I, SHELBURNE SA, Trautner B. Enterococcal Bacteriuria Is Often Managed Inappropriately. Infectious Diseases Society of America Annual Meeting, 2010.
58. Shelburne SA, Olsen RJ, Brennan RG, Musser JM. Identification of the molecular mechanism by which CcpA contributes to the pathogenesis of streptococcal infection. Program and abstracts of the American Society for Clinical Investigation/Association of American Physicians Joint Meeting, Chicago, IL, 2009.
59. SHELBURNE SA, Horstmann N, Brennan RG, and Musser JM. Interaction between transcriptional regulatory proteins contributes to the pathogenesis of invasive group A streptococcal disease. Program and abstracts of the American Society for Clinical Investigation/Association of American Physicians Joint Meeting, 2009.
60. Shelburne SA, Keith D, Horstaman N, Sumby P, Davenport M, Graviss EA, Brennan RG, Musser JM. A direct link between carbohydrate utilization and virulence in the major human pathogen group A Streptococcus. Program and abstracts of the American Society for Clinical Investigation/Association of American Physicians Joint Meeting, Chicago, IL, 2008.
61. Shelburne SA, Keith D, Davenport M, Musser JM. Role of extracellular polysaccharide degrading enzymes in group A streptococcal pathogenesis. Program and abstracts of the 2008 IDSA/ICAAC Joint Meeting, Washington, DC. (poster presentation), 2008.
62. Shelburne SA, Keith DB, Sumby P, Fang H, Sitkiewicz I, Austin CM, Graviss EA, Chow DC, Musser JM. Group A Streptococcus uses human salivary α-amylase to catabolize glucans. Program and abstracts of the American Society for Clinical Investigation/Association of American Physicians Joint Meeting, Chicago, IL, 2007.
63. Shelburne SA, Sumby P, Sitkiewicz I, Okorafor N, Granville G, Patel P, Voyich J, Hull R, DeLeo FR, Musser JM. Maltodextrin utilization plays a key role in the ability of group A Streptococcus to colonize the oropharynx. Program and abstracts of the 44th Annual IDSA Meeting, Toronto, ON, (oral presentation), 2006.
64. Shelburne SA, Granville C, Tokuyama M, Sitkiewicz I,, Patel P, Musser JM. Growth characteristics and virulence factor production by group A Streptococcus during cultivation in human saliva. Program and abstracts of the 43rd Annual IDSA Meeting, San Francisco, CA,, 2005.
65. Daver NG, Shelburne SA, Atmar R, Giordano T, Reitman C, White AC Jr. IV to oral step-down therapy comparable to parenteral therapy for staphylococcal osteomyelitis. Program and abstracts of the 43rd Annual IDSA Meeting, San Francisco, CA,, 2005.
66. Sutarwala A, Rueda A, Shelburne SA. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. Programs and abstracts of the 43rd Annual IDSA meeting, San Francisco, CA,, 2005.
67. Shelburne SA, Darcourt J, White AC, Greenberg S, Hamill RJ, Atmar R, Visnegarwala F. Incidence and risk factors for immune reconstitution inflammatory syndrome (IRIS) among patients with Cryptococcus neoformans infection. Program and abstracts of the 11th Annual Conference on Retroviruses and Opportunistic Infections, San Francisco, CA,, 2004.
68. Shelburne SA, Darcourt J, Visnegarwala F, Giordano T, Graviss E, Hamill RJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in HIV-infected patients infected with Mycobacterium tuberculosis, Mycobacterium avium complex, or Cryptococcus neoformans who are treated with highly active antiretroviral therapy. Program and abstracts of the 41st Annual IDSA Meeting, San Diego, CA,, 2003.
69. SHELBURNE SA, Giordano TP, Visnegarwala F, Graviss EA, Darcourt J, Hamill RJ, White AC. Prevalence of immune reconstitution inflammatory syndrome (IRIS) during highly active antiretroviral therapy (HAART) in HIV-infected patients with Mycobacterium tuberculosis (MTB), Mycobacterium avium complex (MAC), or Cryptococcus neoformans infection. Infectious Diseases Society of America Annual Meeting, 2003.
70. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Gathe JC, Trautner B, Visnegarwala F, Atmar RL. Immune reconstitution inflammatory syndrome (IRIS): emergence of unique syndrome during highly active antiretroviral therapy (HAART). 39th Annual IDSA Meeting, San Francisco, CA,, 2001.

Book Chapters

1. Shelburne SA, Hamill RJ. Infectious Diseases: Mycotic. In: Current Medical Diagnosis and Treatment, 2018.
2. Shelburne SA, Hamill RJ. Infectious diseases: Mycotic. In: Current Medical Diagnosis and Treatment, 2017.
3. Shelburne SA; Lewis RE; Kontoyiannis D. Clinical Approach To Infections in the Compromised Host. In: Hematology, Basic Principles and Practice, Sixth, 2017.
4. Shelburne SA, Hamill RJ. Infectious diseases: Mycotic. In: Current Medical Diagnosis and Treatment, 2016.
5. Shelburne SA,Hamill RJ,. Infectious diseases: Mycotic. In: Current Medical Diagnosis and Treatment, 2015.
6. Shelburne SA, Hamill RJ. Infectious Diseases: Mycotic. In: Current Medical Diagnosis and Treatment, 2014.
7. Shelburne SA, Hamill RJ. Infectious diseases: Mycotic. In: Current Medical Diagnosis and Treatment, 2013.
8. Shelburne SA, Lewis RE, Kontoyiannis D. Clinical Approach To Infections In The Compromised Host. In: Hematology, Basic Principles and Practice. Sixth, 2012.
9. Shelburne SA, Hamill RJ. Infectious diseases: Mycotic. In: Current Medical Diagnosis and Treatment, 2012.
10. Shelburne SA, Musher DM. Management of Gram-Positive Bacterial Disease: Staphylococcus aureus, Streptococcal, Pneumococcal, and Enterococcal Infections. In: Principles and Practice of Cancer Infectious Diseases. Humana Press, 409, 2011.
11. Shelburne SA, Hamill RJ. Infectious diseases: Mycotic. In: Current Medical Diagnosis and Treatment. Appleton & Lange, 2011.
12. Shelburne SA, Hamill RJ. Infectious diseases: Mycotic. In: Current Medical Diagnosis and Treatment. Appleton & Lange, 2010.
13. Shelburne SA, Hamill RJ. Infectious diseases: Mycotic. In: Current Medical Diagnosis and Treatment. Appleton & Lange: Stamford, CT, 2009.
14. Shelburne, SA. Empirical use of Fluconazole in critically ill patients: good study but what was the hold-up?. In: Annals of Internal Medicine. 1, 58-9, 2009.
15. Shelburne SA. Immune reconstitution inflammatory syndrome. In: Clinical Infectious Diseases. Cambridge University Press: New York, NY, 2008.
16. Shelburne SA, Hamill RJ. Infectious diseases: Mycotic. In: Current Medical Diagnosis and Treatment. Appleton & Lange: Stamford, CT, 2008.
17. Hamill RJ, Shelburne SA. Infectious diseases: Mycotic. In: Current Medical Diagnosis and Treatment 2007. Appleton & Lange: Stamford, CT, 2007.
18. Hamill RJ, Shelburne SA. Infectious diseases: Mycotic. In: Current Medical Diagnosis and Treatment 2006. Appleton & Lange: Stamford, CT, 2006.
19. Hamill RJ, Shelburne SA. Infectious diseases. In: Medical Secrets. 4th. Hanley & Belfus, Inc: Philadelphia, PA, 2005.
20. Shelburne SA, Shandera WX. Infectious diseases: Viral & rickettsial. In: Current Medical Diagnosis and Treatment 2004. Appleton & Lange: Stamford, CT, 2004.
21. Shelburne SA, Shandera WX. Infectious diseases: Viral & rickettsial. In: Current Medical Diagnosis and Treatment 2003. Appleton & Lange: Stamford, CT, 2003.

Letters to the Editor

1. Shelburne SA. Empirical use of fluconazole in critically ill patients: good study, but what was the hold-up?. Ann Intern Med 150: 58-9; author reply 59-60, 2009.